Kathryn L Laurie1, Paul Lee2, Alfred Rademaker3, Todd A Alonzo4, Yi-Cheng Wang5, Bayard L Powell6, Diana Wu7, Richard Larson8, Matthew Kutny9, John Gregory10, Nobuko Hijiya11, James Feusner12. 1. Department of Pediatric Hematology/Oncology, Goryeb Children's Hospital of Morristown Medical Center, Morristown, New Jersey, USA. 2. AbbVie, Chicago, Illinois, USA. 3. Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. 4. Department of Preventive Medicine, University of Southern California, Los Angeles, California, USA. 5. Department of Biostatistics, University of Southern California, Los Angeles, California, USA. 6. Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, USA. 7. St. Jude Children's Research Hospital, Memphis, Tennessee, USA. 8. University of Chicago, Chicago, Illinois, USA. 9. Department of Pediatrics, Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA. 10. Novartis, East Hanover, New Jersey, USA. 11. Division of Hematology/Oncology/Stem Cell Transplant, Columbia University Medical Center, New York, New York, USA. 12. Division of Pediatric Hematology Oncology, Children's Hospital & Research Center Oakland, Benioff Children's Hospital Oakland, Oakland, California, USA.
Abstract
OBJECTIVE: To compare outcomes of obese and nonobese pediatric patients with acute promyelocytic leukemia (APL) from the Cancer and Leukemia Group B trial (CALGB) 9710 and the Children's Oncology Group trial AAML0631. METHODS: Data including demographics, adverse events, overall and event-free survival (EFS) were analyzed. RESULTS: The prevalence of obesity was 34% on C9710 and 35% on AAML0631. There was significantly lower overall and EFS in the obese population on multivariable analysis on AAML0631 but not on CALGB 9710. Eleven patients died during therapy or in follow-up. CONCLUSION: The prevalence of obesity is higher in pediatric patients with APL compared to the general population. The decreased EFS and OS in obese patients on AAML0631 suggest that the presence of obesity can influence outcomes using the most current treatment. These findings support the need for further research on the potential role of obesity in pediatric APL leukemogenesis.
OBJECTIVE: To compare outcomes of obese and nonobese pediatric patients with acute promyelocytic leukemia (APL) from the Cancer and Leukemia Group B trial (CALGB) 9710 and the Children's Oncology Group trial AAML0631. METHODS: Data including demographics, adverse events, overall and event-free survival (EFS) were analyzed. RESULTS: The prevalence of obesity was 34% on C9710 and 35% on AAML0631. There was significantly lower overall and EFS in the obese population on multivariable analysis on AAML0631 but not on CALGB 9710. Eleven patients died during therapy or in follow-up. CONCLUSION: The prevalence of obesity is higher in pediatric patients with APL compared to the general population. The decreased EFS and OS in obese patients on AAML0631 suggest that the presence of obesity can influence outcomes using the most current treatment. These findings support the need for further research on the potential role of obesity in pediatric APL leukemogenesis.
Authors: M S Tallman; J W Andersen; C A Schiffer; F R Appelbaum; J H Feusner; A Ogden; L Shepherd; C Willman; C D Bloomfield; J M Rowe; P H Wiernik Journal: N Engl J Med Date: 1997-10-09 Impact factor: 91.245
Authors: Nobuko Hijiya; John C Panetta; Yinmei Zhou; Emily P Kyzer; Scott C Howard; Sima Jeha; Bassem I Razzouk; Raul C Ribeiro; Jeffrey E Rubnitz; Melissa M Hudson; John T Sandlund; Ching-Hon Pui; Mary V Relling Journal: Blood Date: 2006-08-17 Impact factor: 22.113
Authors: Matthew A Kutny; Todd A Alonzo; Robert B Gerbing; Yi-Cheng Wang; Susana C Raimondi; Betsy A Hirsch; Cecilia H Fu; Soheil Meshinchi; Alan S Gamis; James H Feusner; John J Gregory Journal: J Clin Oncol Date: 2017-08-02 Impact factor: 44.544